Press release
Graft Versus Host Disease Treatment Market: Epidemiology, Therapies, Companies Working, DelveInsight | Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics,
Graft Versus Host Disease Treatment Market
Graft Versus Host Disease therapies such as NIKTIMVO, JAKAVI/JAKAFI MOA, IMBRUVICA, RYONCIL/TEMCELL HS, and others are expected to boost the Graft Versus Host Disease Market [https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] in the upcoming years.
DelveInsight has launched a new report on "Graft Versus Host Disease - Market Insights, Epidemiology, and Market Forecast-2034 [https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" that delivers an in-depth understanding of the Graft Versus Host Disease, historical and forecasted epidemiology as well as the Graft Versus Host Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Graft Versus Host Disease Market Report:
*
According to DelveInsight's analysis, the GVHD Market in the 7MM was valued at approximately USD 1,301.8 million in 2023. It is projected to grow at a CAGR of 8.2% from 2025 to 2034.
*
Various therapies, including steroids, NIKTIMVO, JAKAVI/JAKAFI MOA, IMBRUVICA, RYONCIL/TEMCELL HS, and ORENCIA, are available for managing GVHD.
*
GVHD-focused companies like CSL Behring, Equillium, MaaT Pharma, and REGiMMUNE are advancing their clinical trial assets, driving innovation and creating significant growth opportunities in the GVHD market.
*
DelveInsight estimates that in 2023, there were approximately 52 thousand GVHD cases in the 7MM. Of these, the United States accounted for 45%, EU4 and the UK represented 39%, and Japan had 16% of the cases.
*
In November 2024, Equillium expedited the timeline for completing EQ001 in the Phase III EQUATOR study for GVHD, aiming for completion by Q1 2025.
*
According to DelveInsight's epidemiology model, there were approximately 57 thousand allogeneic transplant cases and nearly 52 thousand cases of Graft Versus Host Disease (GVHD) across the 7MM in 2023, with these numbers expected to rise by 2034.
*
In 2023, the US reported the highest number of GVHD cases among the 7MM, with around 24 thousand cases, a number expected to increase by 2034.
*
In the EU4 and the UK, Germany had the highest number of GVHD cases in 2023, reporting approximately 8 thousand cases, followed by Italy and France with around 3 thousand cases each. Spain had the lowest number, with approximately 2,700 cases.
*
Key Graft Versus Host Disease companies such as Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Plexxikon, Medsenic, Xenothera, and others are evaluating new drugs for Graft Versus Host Disease to improve the treatment landscape.
Key benefits of the Graft Versus Host Disease market report:
*
Graft Versus Host Disease market report covers a descriptive overview and comprehensive insight of the Graft Versus Host Disease Epidemiology and Graft Versus Host Disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
*
The Graft Versus Host Disease market report provides insights on the current and emerging therapies.
*
Graft Versus Host Disease market report provides a global historical and forecasted market covering drug outreach in 7MM.
*
The Graft Versus Host Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Graft Versus Host Disease market.
Got queries? Click here to know more about the Graft Versus Host Disease Market Landscape [https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr].
Graft Versus Host Disease Overview
Graft Versus Host Disease (GVHD) is an immune disorder that occurs following transplant procedures when immune cells (T cells) from the donor (the graft) attack the tissues (healthy cells) of the recipient. This condition is a common side effect after an allogeneic bone marrow transplant and, in some cases, can be life-threatening. Prior to undergoing an allogeneic stem cell transplant, the patient typically receives high doses of chemotherapy or radiation to eliminate diseased cells and prepare the body for the donor cells.
GVHD primarily occurs in two forms: acute and chronic. A recipient of an allogeneic transplant may develop either type, both types, or none at all. On average, GVHD affects about 30-50% of patients who undergo allogeneic hematopoietic cell transplantation.
Graft Versus Host Disease Market Outlook
The dynamics of the Graft Versus Host Disease market [https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] is anticipated to change in the coming years owing to the expected launch of emerging therapies by key companies such as Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Plexxikon, Medsenic, Xenothera, and others during the forecast period 2020-2034.
Scope of the Graft Versus Host Disease Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Graft Versus Host Disease Companies: Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Plexxikon, Medsenic, Xenothera, and others
*
Graft Versus Host Disease Therapeutic Assessment: Graft Versus Host Disease current marketed and Graft Versus Host Disease emerging therapies
*
Graft Versus Host Disease Market Dynamics: Graft Versus Host Disease market drivers and Graft Versus Host Disease market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Graft Versus Host Disease Unmet Needs, KOL's views, Analyst's views, Graft Versus Host Disease Market Access and Reimbursement
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Graft Versus Host Disease Patient Share (%) Overview at a Glance
5. Graft Versus Host Disease Market Overview at a Glance
6. Graft Versus Host Disease Disease Background and Overview
7. Graft Versus Host Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Graft Versus Host Disease
9. Graft Versus Host Disease Current Treatment and Medical Practices
10. Unmet Needs
11. Graft Versus Host Disease Emerging Therapies
12. Graft Versus Host Disease Market Outlook
13. Country-Wise Graft Versus Host Disease Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Graft Versus Host Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about Graft Versus Host Disease Market Outlook 2034 [https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr].
Related Reports:
Graft Versus Host Disease Pipeline Insights, DelveInsight
"Graft Versus Host Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Graft Versus Host Disease market. A detailed picture of the Graft Versus Host Disease pipeline landscape is provided, which includes the disease overview and Graft Versus Host Disease treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=graft-versus-host-disease-treatment-market-epidemiology-therapies-companies-working-delveinsight-biocon-medac-gmbh-maat-pharma-elsalys-biotech-glia-syndax-pharmaceuticals-asc-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Graft Versus Host Disease Treatment Market: Epidemiology, Therapies, Companies Working, DelveInsight | Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, here
News-ID: 3991390 • Views: …
More Releases from ABNewswire
Understanding Magnetic Switches: Types, Working Principles, and Applications
A magnetic switch is a versatile electrical device that operates by responding to magnetic fields. From Hall Effect to reed switches, explore their functions, types, and diverse applications.
What is a Magnetic Switch?
A magnetic switch is an electrical device that operates by responding to the presence of a magnetic field. It functions by closing or opening its contacts based on the strength of the magnetic field. Specifically, the switch remains closed…
Innovating embedded downlight technology: Leading the global trend of intelligen …
The strong rise of China's manufacturing industry has profoundly reshaped the technological landscape and development trajectory of embedded downlights. With its unparalleled industrial chain advantages, continuous technological innovation, and significant cost-effectiveness, Chinese enterprises have risen from participants in the global lighting industry to undisputed leaders. This transformation goes far beyond the huge production scale; it lies in the thorough innovation of the core technical content and application boundaries of embedded…
North China Electric Power University Foreign Aid Training Program Visits Yiyuan …
On July 23, 2025, the Electrical Industry Training Program of North China Electric Power University's Foreign Aid Project visited Yiyuan Technology for an exchange visit. The purpose was to gain in-depth insights into the company's innovations in renewable energy technology promotion and application [https://www.yiyen.com/about/], and to build bridges connecting university-enterprise cooperation with foreign aid initiatives.
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-1.jpg
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-3.jpg
Upon arrival, the delegation received a warm welcome from company leadership and the reception…
Pure Sine Wave Low Frequency Inverter Charger
Pure sine wave low frequency inverter [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] is widely used and suitable for a variety of scenarios. In terms of home backup power, it can provide reliable power during power outages, ensuring that essential appliances such as refrigerators, air conditioners and medical equipment continue to operate . For solar power generation systems, Inverter charger [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] can converter DC Power from Battery, which charged by solar panels, into clean alternating current…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
